Skip to content
FY'25FY'24FY'23FY'22
$98.05M+5,883%$1.64M-98.2%$90.12M-15.1%$106.09M-47.4%
$19.93M$0-100%$93.82M-26.5%$127.7M+175%
$118.81M+4,459%$2.61M-98.6%$187.64M-22.8%$243.05M-4.1%
$121.74M+1,876%$6.16M-96.8%$190.8M-31.1%$277.08M-3.3%
$1.28M-17.9%$1.56M-76.9%$6.76M+125%$3M-64.1%
$9.71M-60.7%$24.7M-12.9%$28.37M+16.6%$24.34M-35.7%
$42.92M-24.4%$56.78M+26.1%$45.02M-14.4%$52.56M-14.3%
$2K$0$0-100%$9K+28.6%
-$160M-37.3%-$116.56M+82.2%-$656.19M-40.9%-$465.78M-56.8%
$78.81M+182%-$96.62M-115%-$45.02M-120%$224.52M-0.3%
$121.74M+1,876%$6.16M-96.8%$190.8M-31.1%$277.08M-3.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Kalaris Therapeutics, Inc. Common Stock's total assets?
Kalaris Therapeutics, Inc. Common Stock (KLRS) holds $109.8M in total assets, up 6.5% year over year.
How much debt does Kalaris Therapeutics, Inc. Common Stock have?
Kalaris Therapeutics, Inc. Common Stock carries $1.4M in total debt against $68.6M of shareholders' equity, a debt-to-equity ratio of 0.02.
How much cash does Kalaris Therapeutics, Inc. Common Stock have?
Kalaris Therapeutics, Inc. Common Stock holds $34.4M in cash and equivalents.
Can Kalaris Therapeutics, Inc. Common Stock cover its short-term obligations?
Its current ratio is 12.19 — current assets exceed current liabilities.
Where does Kalaris Therapeutics, Inc. Common Stock's balance sheet data come from?
Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.